Adding Ruxolitinib to Capecitabine Fails To Improve Outcomes in Pancreatic Cancer

Share this content:
Addition of ruxolitinib to second-line capecitabine therapy was well tolerated but did not improve clinical outcomes.
Addition of ruxolitinib to second-line capecitabine therapy was well tolerated but did not improve clinical outcomes.

Among patients with metastatic pancreatic cancer, the addition of ruxolitinib to second-line capecitabine therapy was well tolerated but did not improve clinical outcomes, according to a study being presented at the 2017 Gastrointestinal Cancers Symposium.1

Because the JAK-STAT pathway plays a role in the pathogenesis of pancreatic cancer, researchers conducted a phase 2 study to evaluate the activity of JAK1/2 inhibition with ruxolitinib in combination with capecitabine among patients with metastatic pancreatic cancer and evidence of systemic inflammation. The study showed a survival benefit with the combination compared with capecitabine alone.

Researchers developed 2 phase 3 trials to assess the efficacy and safety of ruxolitinib plus capecitabine in patients with advanced pancreatic cancer requiring second-line therapy. For the Janus 1 trial (ClinicalTrials.gov Identifier: NCT02117479) and the Janus 2 trial (ClinicalTrials.gov Identifier: NCT02119663), investigators randomly assigned 321 and 86 patients, respectively, 1:1 to receive ruxolitinib plus capecitabine or placebo plus capecitabine.

Based on efficacy findings of a planned interim analysis, investigators terminated the study early. Results showed no significant difference in median overall survival between the 2 arms in either Janus 1 (hazard ratio [HR], 0.969; 95% CI, 0.75-1.26; P = .409) or Janus 2 (HR, 1.584; 95% CI, 0.89-2.83; P = .942).

In Janus 1, median progression-free survival was 43 days with ruxolitinib vs 44 days with placebo (HR, 1.056; 95% CI, 0.83-1.35; P = .666); median progression-free survival was 48 days and 61 days, respectively, in the Janus 2 study (HR, 1.166; 95% CI, 0.69-1.98; P = .720).

Less than 5% of patients in each treatment group achieved an overall response.

RELATED: Advanced Pancreatic Cancer: 3 New Agents Improved Outcomes Between 1978-2015

The most common grade 3 to 4 non-hematologic adverse events were abdominal pain, palmar-plantar erythrodysesthesia syndrome, pulmonary embolism, dyspnea, and vomiting. The most frequent grade 3 to 4 hematologic abnormalities were anemia and lymphopenia. Four percent of ruxolitinib-treated patients in Janus 1 and 12% in Janus 2 discontinued treatment due to adverse events compared with 10% and 12% of patients given placebo in Janus 1 and Janus 2, respectively.

Reference

  1. Hurwitz H, Van Cutsem E, Bendell JC, et al. Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2). J Clin Oncol. 2017;35(suppl):4S. Abstract 343.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters